Temporal changes in the prevalence and associates of diabetes-related lower extremity amputations in patients with type 2 diabetes: the Fremantle Diabetes Study by unknown
Baba et al. Cardiovasc Diabetol  (2015) 14:152 
DOI 10.1186/s12933-015-0315-z
ORIGINAL INVESTIGATION
Temporal changes in the prevalence 
and associates of diabetes-related lower 
extremity amputations in patients with type 2 
diabetes: the Fremantle Diabetes Study
Mendel Baba1,2, Wendy A. Davis1, Paul E. Norman3 and Timothy M. E. Davis1*
Abstract 
Background: To determine temporal changes in the prevalence and associates of lower extremity amputation (LEA) 
complicating type 2 diabetes.
Methods:  Baseline data from the longitudinal observational Fremantle Diabetes Study (FDS) relating to LEA and its 
risk factors collected from 1296 patients recruited to FDS Phase 1 (FDS1) from 1993 to 1996 and from 1509 patients 
recruited to FDS Phase 2 (FDS2) from 2008 to 2011 were analysed. Multiple logistic regression was used to determine 
associates of prevalent LEA in individual and pooled phases. Generalised linear modelling was used to examine 
whether diabetes related LEA prevalence and its associates had changed between Phases.
Results: There were 15 diabetes-related LEAs at baseline in FDS1 (1.2 %) and 15 in FDS2 (1.0 %; P = 0.22 after age, 
sex and race/ethnicity adjustment). In multivariable analysis, independent associates of a baseline LEA in FDS1 were 
a history of vascular bypass surgery or revascularisation, urinary albumin:creatinine ratio, peripheral sensory neu-
ropathy and cerebrovascular disease (P ≤ 0.035). In FDS2, prevalent LEA was independently associated with a history 
of vascular bypass surgery or revascularisation, past hospitalisation for/current foot ulcer and fasting serum glucose 
(P ≤ 0.001). In pooled analyses, a history of vascular bypass or revascularisation, past hospitalisation for/current foot 
ulcer at baseline, urinary albumin:creatinine ratio (P < 0.001), as well as FDS Phase as a binary variable [odds ratio (95 % 
confidence interval): 0.28 (0.09–0.84) for FDS2 vs FDS1, P = 0.023] were associated with a lower risk of LEA at study 
entry.
Conclusions: The risk of prevalent LEA in two cohorts of patients with type 2 diabetes from the same Australian 
community fell by 72 % over a 15-year period after adjustment for important between-group differences in diabetes-
related and other variables. This improvement reflects primary care foot health-related initiatives introduced between 
Phases, and should have important individual and societal benefits against a background of a progressively increasing 
diabetes burden.
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Background
There is evidence that the rates of chronic complica-
tions and death associated with diabetes are declining 
in developed countries [1–4], although the burden of 
disease remains high due to a progressive increase in 
diabetes prevalence [5]. In the case of lower extremity 
amputation (LEA), the development of multidisciplinary 
foot clinics and streamlined care pathways in local sec-
ondary and tertiary health care settings has been associ-
ated with significant reductions in the rates of LEA [6–9]. 
Most larger population-based studies have also shown a 
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reduction in the rates of this complication [3, 10–13], but 
some have shown no change [14–16] or an increase [17].
Interpretation of the results of clinic- and population-
based studies is, however, complicated by limitations 
such as use of selected patient samples, a restricted range 
of explanatory and confounding variables, and lack of 
interpretation of the findings in the light of changes in 
management that could have an impact on foot health. 
There is, therefore, the need for an assessment of tem-
poral changes in LEA rates in community-based patient 
groups and in health care systems, both of which are 
well-characterised. The aims of the present study were, 
therefore, (1) to determine whether the prevalence of 
LEA has changed in comprehensively assessed patients 
with type 2 diabetes resident in a large urban Austral-
ian population in the 15  years between 1993–1996 and 
2008–2011, and (2) to assess the relationship between 
any changes in established risk factors for LEA and its 
prevalence over the same period.
Methods
Patients and approvals
We studied participants in the Fremantle Diabetes Study 
Phase 1 (FDS1) and Phase 2 (FDS2) [18]. Both Phases are 
longitudinal observational studies carried out in the same 
postcode-defined geographical area surrounding the port 
city of Fremantle in the state of Western Australia (WA). 
Details of recruitment, sample characteristics including 
classification of diabetes type, and non-recruited patients 
have been published previously [18]. In brief, any patient 
resident in the study catchment area with a clinician-ver-
ified diagnosis of diabetes was eligible. Sources of iden-
tification and/or diagnostic data included public hospital 
inpatient/outpatient clinic lists and laboratory databases, 
notifications by local primary care/specialist physicians 
and allied health services including diabetes education, 
dietetics and podiatry, advertisements in pharmacies and 
local media, and word of mouth. The FDS1 protocol was 
approved by the Human Rights Committee, Fremantle 
Hospital and FDS2 was approved by the Human Research 
Ethics Committee of the Southern Metropolitan Area 
Health Service. All subjects in both Phases gave written 
informed consent.
We identified 2258 eligible FDS1 participants dur-
ing the three-year period between 1993 and 1996 in the 
local population of approximately 120,000 (crude diabe-
tes prevalence 1.9  %) and recruited 1426 (63  %). In the 
case of FDS2, 4639 diabetic patients were identified over 
the same time period between 2008 and 2011 from a 
population of 157,000 (crude prevalence 3.0 %) and 1668 
(36 %) were recruited, including 326 surviving FDS1 par-
ticipants. For FDS1, 1296 (90.9 %) of the recruited cohort 
had type 2 diabetes and, for FDS2, the equivalent figure 
was 1509 (90.4 %).
Overview of assessment procedures
Each FDS1 participant was assessed in detail at baseline 
and invited to attend annual reviews for ≥5  years. For 
FDS2, comprehensive baseline assessments are followed 
by face-to-face assessments biennially rather than annu-
ally, with questionnaire follow-up in alternate years. All 
FDS face-to-face assessments comprise a comprehensive 
questionnaire, physical examination and standard fast-
ing biochemical tests [18]. The focus of the present study 
was the identification of any changes in diabetes-related 
LEA prevalence and associates over the 15 years between 
recruitment periods. For this reason, baseline rather than 
serial data from the two Phases were analysed.
Data collection
For both Phases, diabetes type was assessed from dia-
betes treatment history, BMI, age at diagnosis, nature 
of first presentation, and/or self-identification, and case 
records were consulted for evidence of ketonaemia, as 
well as islet autoantibodies, serum insulin and C-peptide 
levels, if available. Ethnic background was assessed from 
self-selection, country/countries of birth and parents’ 
birth, language(s) spoken at home and, for FDS2, country 
of grandparents’ birth.
In the case of foot assessment, a trained nurse per-
formed (1) palpation of the pedal pulses (dorsalis pedis 
and posterior tibial), (2) measurement of the ankle bra-
chial index (ABI), (3) general foot inspection to detect 
ulceration (defined, for the purposes of the present study, 
as located at or below the level of the malleoli), deformity, 
corns or callus, skin fissures, infections and nail pathol-
ogy) and (4) assessment of peripheral sensory neuropathy 
(PSN) using the clinical features of the Michigan Neu-
ropathy Screening Instrument (MNSI) [19]. PSN was 
defined as a score of >2/8 on the clinical portion of the 
MNSI. The patient was asked about prior foot ulcera-
tion and intermittent claudication was ascertained by 
determining whether pain in the calves came on during 
walking, caused the patient to slow down or stop, and 
resolved with rest. Peripheral arterial disease (PAD) was 
considered present if the ABI was ≤0.90 on either leg or 
a diabetes-related amputation (attributable to PAD) was 
present [20]. A major amputation was defined as through, 
or proximal to, the tarsometatarsal joint, and a minor one 
as distal to this joint [21].
Other chronic complications were ascertained using 
standard criteria. Self-reported stroke and transient 
ischemic attack were amalgamated with prior hospitali-
sations to define baseline cerebrovascular disease status. 
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Patients were considered to have coronary artery disease 
if there was a self-reported history of, or hospitalisa-
tion for, myocardial infarction, angina, coronary artery 
bypass grafting or angioplasty. A subject was considered 
to have retinopathy if any grade of retinopathy, includ-
ing maculopathy, was detected by direct and/or indirect 
ophthalmoscopy in one or both eyes and/or on more 
detailed assessment by an ophthalmologist in FDS1 or 
from retinal photography using a non-mydriatic camera 
in FDS2. The estimated glomerular filtration rate (eGFR) 
was calculated using the chronic kidney disease epidemi-
ology collaboration equation [22]. Details of prior hospi-
talisations accessed through the Western Australian Data 
Linkage System [23] provided important supplementary 
data for ascertainment of coronary heart disease, cer-
ebrovascular disease, foot ulceration, peripheral revas-
cularisation and arterial bypass procedures. Coding error 
rates and missing patient numbers are low (around 1 % or 
less) for vascular complications [24].
Biochemical testing in both Phases of the FDS was car-
ried out in the same nationally accredited diagnostic bio-
chemistry laboratory. Between-run imprecision for all 
methods was <3.5 %, except for urine albumin and serum 
HDL-cholesterol in FDS2, for which it was <5.0 %. Serum 
LDL-cholesterol was estimated using the Friedewald 
equation. For assays that had changed between 1993 and 
the present, calibration equations were applied to stand-
ardize all concentrations to current assays used for FDS2 
[25].
Statistical analysis
The computer package IBM SPSS Statistics 21 (IBM 
Corporation, Somers, NY, US) was used for statistical 
analysis. Data are presented as proportions, mean ± SD, 
geometric mean (SD range), or, median and interquartile 
range (IQR) in the case of variables that do not conform 
to the normal or log-normal distribution. For independ-
ent samples, two way comparisons for proportions were 
performed by Fisher’s exact test, Student’s t test for nor-
mally distributed variables, and the Mann–Whitney 
U-test for variables that were not normally distributed. 
A two-tailed P-value of <0.05 was considered significant. 
Multiple logistic regression with forward conditional 
entry (P < 0.05 for entry, P > 0.05 for removal) was used 
to determine independent associates of prevalent LEA, 
with all clinically plausible variables P < 0.05 considered 
for entry into the model, except for PAD because all 
patients with amputation at baseline were defined as hav-
ing PAD after examination of medical records. General-
ized linear modelling with adjustment for age, sex and 
ethnicity was used to determine whether baseline associ-
ates had changed between Phases.
Results
Patient characteristics
Demographic, socioeconomic, anthropometric and dia-
betes-specific details of participants with type 2 diabetes 
recruited to the two Phases are summarized in Table 1. 
The between-phase differences in cohort characteristics 
have been describe elsewhere [26]. In brief, in FDS2 vs 
FDS1 there was a greater proportion of Aborigines, dia-
betes diagnosis was at a younger age, diabetes duration 
was longer, more were overweight/obese, and alcohol 
consumption was higher but more were current smokers. 
Indices of glycaemic control were lower in FDS2 subjects 
who were more likely to be insulin-treated, and systolic 
blood pressure and serum lipid profiles were better con-
sistent with more intensive antihypertensive and lipid-
lowering therapy. Although fewer FDS2 patients had 
microalbuminuria and an eGFR  <60  mL/min/1.73  m2, 
they were more likely to have retinopathy and neuropa-
thy. They were, however, less likely to have intermittent 
claudication and PAD against a background of more fre-
quent prior vascular bypass surgery or peripheral revas-
cularisation procedures.
Baseline diabetes related amputation prevalence 
and associates
At baseline, 15 patients had undergone prior LEA in 
both FDS Phases, representing prevalence rates of 1.0 %, 
and 1.2 % in FDS2 vs FDS1, respectively (P = 0.72). The 
age-, sex- and ethnicity-adjusted difference between the 
Phases for LEA prevalence was also not significant [dif-
ference (95 % confidence interval) −0.2 (−0.6 to 0.9)  %, 
P  =  0.22]. There was a non-significant trend towards 
fewer major LEAs in FDS2 vs FDS1 (P = 0.07) but no dif-
ference in the prevalence of minor LEAs (P = 0.90). No 
patient presented with both a minor and major LEA in 
either Phase.
In multiple logistic regression analysis, independ-
ent associates of a baseline LEA in FDS1 were a history 
of vascular bypass surgery or revascularisation, urinary 
albumin:creatinine ratio, PSN and cerebrovascular dis-
ease (see Table 2). In FDS2, prevalent LEA was also inde-
pendently associated with a history of vascular bypass 
surgery or revascularisation, but also past hospitalisation 
for foot ulcer/current foot ulcer and the fasting serum 
glucose (see Table 2).
When FDS1 and FDS2 data were combined, those with 
LEA at baseline were diagnosed at a younger age and had 
a longer duration of diabetes than those without LEA, 
were less likely to be in paid employment, and a greater 
proportion were Aboriginal (see Table  3). Patients with 
a LEA were more likely to be treated with insulin (with 
or without oral blood glucose-lowering agents), but their 
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Table 1 Baseline characteristics of Fremantle Diabetes Study Phase 1 (FDS1) and 2 (FDS2) participants with type 2 diabe-
tes
FDS1 FDS2 Difference (95 % CI) P-value*
Number 1296 1509
Age (years) 64.0 ± 11.3 65.4 ± 11.7 1.4 (0.6–2.3) <0.001
Sex (% male) 48.6 51.8 3.2 (−0.5 to 6.9) 0.032
Ethnic background (%)
 Anglo-Celt 61.4 52.6 −8.9 (−12.5 to −5.2) <0.001
 Southern European 17.7 12.9 −4.9 (−7.6 to −2.2) <0.001
 Other European 8.5 7.4 −1.1 (−0.9 to 3.1) 0.20
 Asian 3.4 4.3 0.9 (−0.5 to 2.3) 0.14
 Aboriginal 1.5 7.1 5.6 (4.2–7.1) <0.00
 Other 7.5 15.8 8.4 (6.0–10.7) <0.001
Age at diabetes diagnosis (years) 57.9 ± 11.7 55.6 ± 12.4 −2.3 (−3.2 to 1.4) <0.001
Duration of diabetes (years) 4.0 (1.0–9.0) 8.0 (2.7–15.4) 3.7 (3.2–4.3) <0.001
Education beyond primary level (%) 74.0 86.8 12.8 (9.8–15.7) <0.001
Paid employment (%) 17.5 31.0 13.6 (10.4–16.7) <0.001
Married/de facto relationship (%) 65.7 62.7 −3.0 (−6.5 to 0.6) 0.79
Alcohol use (standard drinks/day) 0 (0–0.8) 0.1 (0–1.2) 0.2 (0.1–0.4) 0.003
Smoking status (%)
 Never 44.7 45.4 0.7 (−3.0 to 4.4) 0.054
 Ex- 40.2 43.9 3.6 (−0.03 to 7.3) 0.29
 Current 15.1 10.7 −4.5 (−7.0 to −2.0) <0.001
BMI (kg/m2) 29.6 ± 5.4 31.3 ± 6.1 1.7 (1.3–2.1) <0.001
Obese by waist circumference (%)a 64.5 70.9 6.4 (2.9–9.9) <0.001
Overweight/obese by waist:hip ratio (%)b 74.2 82.7 8.5 (5.4–11.6) <0.001
Fasting serum glucose (mmol/L) 8.0 (6.5–10.3) 7.2 (6.2–8.9) −0.8 (−1.0 to −0.6) <0.001
HbA1c (%) 7.2 (6.2–8.5) 6.8 (6.2–7.7) −0.3 (−0.4 to −0.2) <0.001
HbA1c (mmol/mol) 55 (44–69) 51 (44–61) −3.5 (−4.8 to −2.1) <0.001
Diabetes treatment (%)
 Diet 31.9 24.6 −7.3 (−10.7 to −4.0) <0.001
 Oral agents 56.0 53.4 −2.6 (−6.3 to 1.1) 0.075
 Insulin ± oral agents 12.1 22.0 9.9 (7.2–12.7) <0.001
Systolic blood pressure (mmHg) 151 ± 24 146 ± 22 −5.1 (−6.8 to −3.4) <0.001
Diastolic blood pressure (mmHg) 80 ± 11 80 ± 12 −0.3 (−1.1 to 0.6) 0.66
On antihypertensive therapy (%) 50.9 72.6 21.7 (18.2–25.2) <0.001
On renin-angiotensin blockers (%) 21.8 64.3 42.4 (39.1–45.8) <0.001
Total serum cholesterol (mmol/L) 5.5 ± 1.1 4.4 ± 1.1 −1.1 (−1.2 to −1.0) <0.001
Serum HDL cholesterol (mmol/L) 1.06 ± 0.3 1.24 ± 0.3 0.18 (0.15–0.20) <0.001
Serum LDL cholesterol (mmol/L) 3.3 ± 0.91 2.3 ± 0.9 −1.0 (−1.1 to −0.9) <0.001
Serum triglycerides (mmol/L) 2.2 (1.2–3.9) 1.5 (0.9–2.5) −0.9 (−1.0 to −0.7) <0.001
On lipid modifying treatment (%) 10.5 67.5 56.9 (54.0–59.8) <0.001
Taking aspirin (%) 22.0 36.6 14.6 (11.3–17.9) <0.001
Microalbuminuria or worse (%) 56.4 40.0 −16.4 (−20.0 to −12.7) <0.001
eGFR <60 mL/min/1.73 m2 (%) 24.2 16.5 –7.8 (−10.8 to −4.8) <0.001
Any retinopathy (%) 16.4 22.4 6.0 (3.0–9.1) 0.001
Peripheral sensory neuropathy (%) 30.8 58.2 27.4 (23.9–31.0) <0.001
Ischaemic heart disease (%) 29.6 27.8 −1.8 (−5.1 to 1.6) 0.32
Cerebrovascular disease (%) 10.0 8.5 −1.4 (−3.6 to 0.8) 0.21
Peripheral arterial disease (%) 29.3 22.6 −6.7 (−10.0 to −3.5) <0.001
Intermittent claudication (%) 14.0 9.2 −4.8 (−7.2 to −2.4) <0.001
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total serum cholesterol was lower. They had a higher 
urine albumin:creatinine ratio and were more likely to 
have an eGFR  <60  mL/min/1.73  m2, consistent with 
more frequent micro- and macrovascular complications 
including retinopathy, PSN, ischaemic heart disease, cer-
ebrovascular disease, PAD, intermittent claudication, as 
well as past hospitalisation for, or current, foot ulcer, and 
a history of vascular bypass surgery and/or peripheral 
revascularisation.
In multiple logistic regression analysis, the independ-
ent associates of amputation at baseline in the pooled 
FDS1 and FDS2 datasets included a history of vascu-
lar bypass or revascularisation, past hospitalisation for 
foot ulcer or a foot ulcer at baseline, and higher urinary 
albumin:creatinine ratio. After adjusting for these vari-
ables in the most parsimonious model and then adding 
FDS Phase as a binary independent variable, Phase 2 was 
associated with significantly lower risk of a diabetes-
related amputation at study entry [odds ratio (95 % confi-
dence interval): 0.28 (0.09–0.84), P = 0.023; Table 4].
Discussion
The key finding in the present study is that the risk of 
prevalent amputation in two community-based cohorts 
of patients with type 2 diabetes from the same urban 
Australian postcode-defined area fell by 72  % over a 
15-year period after adjustment for important between-
group differences in diabetes-related and other vari-
ables. This observation is consistent with recent analyses 
of large US [3, 11] and Australian [27, 28] population 
databases, although there was limited access to risk fac-
tor and other data in each of these four studies. Because 
the present substantial reduction in LEA prevalence was 
independent of improvements in medical and surgi-
cal management of diabetes and cardiovascular disease 
in FDS2 compared with FDS1 patients, there is a strong 
implication that other factors, including the introduction 
of government-funded access to regular podiatry services 
between FDS Phases [29] and the increased availability of 
high risk foot clinics in public hospitals, were responsi-
ble. Indeed, a UK primary care study in 1998 comparing 
intensive foot care (including more frequent podiatry and 
associated services) with usual care over 2 years found a 
similar 70 % reduction in amputation rates [30], while a 
second UK study also showed a substantial fall in diabe-
tes-related LEAs subsequent to improved organization of 
diabetes-related foot care [6].
Epidemiological context
The residents of the FDS catchment area appear repre-
sentative of the general Australian population. Socio-
economic data relating to income, employment, housing, 
Data are proportions, mean ± SD, geometric mean (SD range), median (IQR) or mean difference (95 % CI)
a Waist circumference ≥102.0 cm males, ≥88.0 cm females
b Waist:hip ratio ≥0.95 males, ≥0.80 females
* Age-, sex- and ethnicity-adjusted for interaction between Phases
Table 1 continued
FDS1 FDS2 Difference (95 % CI) P-value*
Arterial bypass/revascularisation (%) 1.3 3.0 1.7 (0.7–2.8) 0.013
Past hospitalisation for/current foot ulcer 1.6 2.8 1.2 (0.1–2.3) 0.17
Diabetes-related LEA (%) 1.2 1.0 −0.2 (−0.9 to 0.6) 0.22
Diabetes-related major LEA (%) 0.6 0.3 −0.3 (−0.8 to 0.2) 0.07
Diabetes-related minor LEA (%) 0.5 0.7 0.1 (−0.5 to 0.7) 0.90
Table 2 Independent associates of diabetes-related lower extremity amputation at baseline in Fremantle Diabetes Study 
Phase 1 (FDS1) and 2 (FDS2). Odds ratios and 95 % confidence intervals (CI) are shown
FDS1 FDS2
Odds ratio (95 % CI) P-value Odds ratio (95 % CI) P-value
History or peripheral bypass or revascularisation 40.15 (8.02–201.09) <0.001 33.50 (6.93–161.86) <0.001
Past hospitalisation for/current foot ulcer 91.65 (19.40–433.08) <0.001
Fasting serum glucose (increase of 1 mmol/L) 1.36 (1.14–1.62) 0.001
Ln (urinary albumin:creatinine ratio (mg/mmol)) 2.04 (1.25–3.32) 0.004
Cerebrovascular disease 6.11 (1.28–29.16) 0.023
Peripheral sensory neuropathy 7.52 (1.16–49.01) 0.035
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Table 3 Characteristics of pooled Fremantle Diabetes Study Phase 1 (FDS1) and 2 (FDS2) participants with or without a 
diabetes-related lower extremity amputation at baseline. Data are proportions, mean ± SD, geometric mean (SD range), 
median [IQR] or mean difference (95 % CI)
No amputation Amputation P-value
Number 2775 30
Age (years) 64.8 ± 11.5 66.4 ± 10.5 0.45
Sex (% male) 50.2 66.7 0.097
Ethnic background (%) 0.020
 Anglo-Celt 56.8 46.7
 Southern European 15.1 16.7
 Other European 7.9 10.0
 Asian 3.9 0.0
 Mixed/other 12.0 6.7
 Aboriginal 4.3 20.0
Age at diabetes diagnosis (years) 56.7 ± 12.0 50.5 ± 16.1 0.005
Duration of diabetes (years) 5.0 (1.75–13.0) 12.0 (9.0–28.0) <0.001
Education beyond primary level (%) 80.8 78.6 0.81
Paid employment (%) 24.9 7.1 0.027
Married/de facto relationship (%) 64.2 50.0 0.13
Alcohol use (standard drinks/day) 0.11 (0.0–0.75) 0.0 (0.0–1.13) 0.65
Smoking status (%) 0.093
 Never 45.2 26.7
 Ex 41.9 63.3
 Current 12.7 10.0
BMI (kg/m2) 30.5 ± 5.9 28.8 ± 5.3 0.14
Obese by waist circumference (%)a 67.9 69.6 1.0
Overweight/obese by waist:hip ratio (%)b 78.7 81.8 1.0
Fasting serum glucose (mmol/L) 7.5 (6.2–9.6) 7.6 (6.0–10.9) 0.83
HbA1c (%) 7.0 (6.2–8.1) 7.1 (6.5–8.6) 0.40
HbA1c (mmol/mol) 53 (44–65) 54 (48–70)
Diabetes treatment (%) <0.001
 Diet 28.2 10.0
 Oral agents 54.8 33.3
 Insulin ± oral agents 17.0 56.7
Systolic blood pressure (mmHg) 148 ± 23 154 ± 33 0.33
Diastolic blood pressure (mmHg) 80 ± 12 79 ± 13 0.61
On antihypertensive therapy (%) 68 ± 19 75 ± 25 0.047
On renin-angiotensin blockers (%) 16.9 23.3 0.33
Total serum cholesterol (mmol/L) 4.9 ± 1.2 4.4 ± 1.2 0.034
Serum HDL cholesterol (mmol/L) 1.16 ± 0.34 1.11 ± 0.32 0.46
Serum triglycerides (mmol/L) 1.8 (1.0–3.2) 1.8 (1.1–2.9) 0.74
Urinary albumin:creatinine ratio 4.0 (1.1–14.7) 23.3 (4.5–121.6) <0.001
On lipid modifying treatment (%) 41.1 46.7 0.58
Taking aspirin (%) 29.7 40.0 0.23
eGFR <60 mL/min/1.73 m2 (%) 19.8 46.7 0.001
Any retinopathy (%) 19.2 53.8 <0.001
Peripheral sensory neuropathy (%) 45.5 82.6 <0.001
History of ischaemic heart disease (%) 28.4 46.7 0.040
History of cerebrovascular disease (%) 8.9 36.7 <0.001
Peripheral arterial disease (%) 24.9 100.0 <0.001
Self-reported intermittent claudication (%) 11.2 33.3 0.001
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transportation and a range of other variables collected 
in the 2006 Australian census (which was conducted 
between FDS1 and FDS2) for the FDS catchment area 
show an average Index of Relative Socio-economic 
Advantage and Disadvantage [31] of 1033 with a range 
by postcode of 977-1113, figures similar to the national 
mean ±  SD which are set at 1000 ±  100. In relation to 
diabetes-related foot health, this became a national 
health priority in 1998 [32], 2 years after FDS1 recruit-
ment had closed. Access to diabetes-related allied health 
services in Australia has been largely through govern-
ment-funded care plans in which primary care practi-
tioners can refer patients for up to five appointments per 
year. Foot care is an integral part of initial general diabe-
tes education which is available under this scheme, and 
there has been a progressive increase in podiatry referrals 
since the scheme was introduced in 2004 [29]. Austral-
ian national recommendations, which were published in 
2011, include at least annual pedal examination for all 
people with diabetes [33]. These considerations suggest 
that the present findings are generalizable to the Aus-
tralian population and that they reflect intensification of 
government-supported foot health initiatives.
A recent assessment of available data has suggested 
that diabetes-related LEAs have increased 30  % in Aus-
tralia over approximately a decade since the late 1990s 
[34]. Although this conclusion was based on dispa-
rate data sources without patient-level data, including 
whether individual patients had multiple hospitalisations 
for LEA [35, 36], the approximate doubling of diabetes 
prevalence over the same time period [18, 35] would be 
expected to increase hospitalisations for LEA on its own. 
Our data suggest that, although the burden of diabetes is 
increasing, management strategies that prevent diabetic 
foot disease have been successful since the FDS1 recruit-
ment period in the 1990s, thus attenuating the risk of 
LEA even though absolute numbers are increasing.
Risk factors for amputation and pathophysiological 
considerations
In the FDS2 and pooled multivariable models, we found 
that past hospitalisation for foot ulcer or current foot 
ulceration was strongly and independently associated 
with prevalent LEA, consistent with the results of previ-
ous studies [20, 37, 38]. The FDS1 model included PSN 
but not past/current foot ulcer, but we have shown that 
these two variables are tightly linked in FDS1 patients 
with type 2 diabetes [26]. In addition, vascular bypass 
surgery or other peripheral revascularisation procedures 
were strongly and positively associated in individual and 
pooled models, almost certainly reflecting confounding 
by indication, while all patients with a history of LEA had 
PAD, in accord with other studies of risk factors for dia-
betes-related LEAs [20, 37, 39, 40].
There was a non-significant trend to a reduction in the 
number of major LEAs from Phase 1 to 2. The results 
of European-based retrospective studies investigating 
changes in major LEA amputation rates have been incon-
sistent. For example, significant reductions in diabetes-
related major LEA rates have been found in Denmark 
and one UK centre [8, 41], non-significant reductions 
have been reported in England as a whole [42], and non-
significant increases have been documented in Ireland 
[14]. These differences may reflect study-specific dif-
ferences in case definition (e.g. above the ankle versus 
above the tarsometatarsal joint) and in the frequency of 
vascular surgery and other revascularisation procedures. 
Recent US retrospective data on endovascular surgi-
cal procedures and general population major LEA rates 
between 1996 and 2006 showed a threefold increase in 
endovascular surgery, a 40 % reduction in bypass surgery, 
and a 30 % reduction in LEA [43]. The authors suggested 
that, although endovascular interventions for PAD are 
being performed more often, a causative link to a reduc-
tion in amputations cannot be established on available 
data given selection and other potential biases.
Table 3 continued
No amputation Amputation P-value
Arterial bypass/revascularisation (%) 1.7 56.7 <0.001
Past hospitalisation for/current foot ulcer (%) 1.7 53.3 <0.001
a Waist circumference ≥ 102.0 cm males, ≥ 88.0 cm females
b Waist:hip ratio ≥ 0.95 males, ≥ 0.80 females
Table 4 Independent associates of  diabetes-related lower 
extremity amputation at  baseline in  pooled Fremantle 
Diabetes Study Phase 1 (FDS1) and 2 (FDS2) samples
Odds ratios and 95 % confidence intervals (CI) are shown. After adjusting for the 
most parsimonious model, FDS Phase was added
Odds ratio (95 % CI) P-value
Ln (urinary albumin:creatinine ratio) 1.74 (1.31–2.32) <0.001
History of vascular bypass or revascu-
larisation
24.57 (8.22–73.48) <0.001
Past hospitalisation for/current foot 
ulcer
23.64 (7.80–71.70) <0.001
FDS Phase 2 0.28 (0.09–0.84) 0.023
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We identified urinary albumin:creatinine ratio, but not 
eGFR, as an independent associate of LEA in the multi-
variable models involving FDS1 and pooled data, con-
sistent with previous studies reporting albuminuria as 
an important risk factor [20, 44, 45]. Other studies have 
shown that a low eGFR and end-stage renal disease are 
associated with diabetes-related LEA [10, 46], but albu-
minuria was not available for inclusion as an independ-
ent variable in the multivariable models used. In any 
case, patients with renal impairment are likely to have 
other microvascular and macrovascular complications 
of diabetes such as PSN and PAD [47] which are strongly 
associated with foot ulceration [26], thus contributing 
indirectly to LEA risk.
Given that the substantial reduction in LEA preva-
lence between FDS Phases was independent of improved 
diabetes and cardiovascular management, the question 
arises as to which factors changed with Australian gov-
ernment initiatives to improve foot care in diabetes [29, 
32]. One possibility relates to increased surveillance for 
ulceration and infection. Local factors such as wound 
depth, severity and presence of infection increase LEA 
risk [48–50], and early detection of these aspects of foot 
ulceration would be facilitated by primary care initiatives 
such as care plans [29]. In addition, availability of advice 
on other preventive podiatric measures (such as appro-
priate footwear and strategies to offload pressure points) 
and regular vascular assessments with a view to surgical 
or other intervention, may well have increased between 
FDS Phases through developments such as increased 
referrals to public hospital high risk foot clinics without 
being captured in the present multivariable analyses.
Recent studies have assessed potential pathophysio-
logical mechanisms underlying diabetes-associated LEA. 
In one, there was evidence that increased below-knee 
arterial calcification scores in patients with type 2 diabe-
tes and normal renal function or mild renal impairment 
were independently associated with plasma concentra-
tions of dephospho-uncarboxylated matrix Gla protein, a 
marker of vitamin K status [51]. Although there is pre-
liminary evidence that vitamin K supplementation may 
reduce vascular calcification, especially in patients with 
chronic kidney disease [52], whether this will influence 
rates of LEA complicating diabetes is unknown. There is 
also evidence that increased circulating concentrations 
of advanced glycation end products are associated with 
diabetes-related LEA [53], but this association is attenu-
ated after adjustment for conventional cardiovascular 
risk factors.
Limitations of the present study
The FDS patients in both Phases may have included rela-
tively healthy patients but the unadjusted prevalence of 
diabetes-related LEA in FDS1 (1.2  %) was very close to 
the 1.3  % prevalence reported in two UK community-
based studies conducted between 1988 and 1996 [54, 55]. 
As previously acknowledged [26], it is possible that there 
was a change in aspects of data collection requiring sub-
jective assessment, although we maintained standardised 
procedures for assessment of relevant complications such 
as PAD and PSN. We did not have measures of plantar 
foot pressures, joint range of motion, adequacy of foot-
wear or peripheral tissue oxygenation, factors that have 
been identified as prognostically important in previous 
studies of diabetes-related foot health [39, 56, 57]. In 
addition, we did not have complete data on use of pub-
lic/private podiatry services or attendances at high risk 
foot clinics to assess whether changes in these variables 
contributed independently to the decline in diabetes-
related LEA between Phases. There were limited num-
bers of LEAs but the significant independent associates 
were all clinically plausible. The strengths of the pre-
sent study include its prospective design, relatively large 
patient numbers and detailed baseline assessments in 
each Phase.
Conclusions
The present study has shown that the risk of prevalent 
LEA in two cohorts of patients with type 2 diabetes from 
the same urban Australian community fell substantially 
over a 15-year period after adjustment for important 
between-group differences in diabetes-related and other 
variables. Given its independence from better manage-
ment of diabetes and cardiovascular disease in FDS2 ver-
sus FDS1, this improvement likely reflects the effects of 
government-funded initiatives to increase awareness of, 
and access to, services focussed on diabetes-related foot 
health that were implemented between the two Phases. 
Given the increasing incidence of diabetes and thus bur-
den of disease including complications such as LEA, this 
should have clear benefits at both an individual and soci-
etal level.
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